(Reuters) – Merck has signed eight deals to sell more than a total of 2 million courses of its experimental COVID-19 pill molnupiravir to governments around the world as countries scramble to tame the virus.
It has applied for approval in the United States and said it can make 10 million courses in 2021.
Last week the company reached a deal with the United Nations-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of the pill with a royalty-free license applying to 105 low- and middle-income countries. So far Merck has agreed to license the drug to several India-based generic drugmakers.
The following table lists countries that already expressed interest in the pill, sorted alphabetically:
COUNTRY VOLUME PRICE TIMING OF SOURCE
DELIVERY
Australia 300,000 doses nL1N2R02UO
EU nL1N2R80ZA
France 50,000 doses nP6N2Q901D
Indonesia nL4N2RL2KW
Malaysia 150,000 courses nL1N2R306L
Philippines 300,000 courses 100-150 pesos November 2021 nL4N2RN2GN
($1.97-$2.96) per
pill
Singapore nL1N2R305J
South Korea 20,000 courses nL4N2R21J1
Thailand 200,000 courses nL1N2R00D9
UK nL8N2QX3RK
U.S. 1,700,000 courses $700 per course nL1N2R00D9
(Reporting by Ina Kreutz, Agnieszka Gosciak and Federica Urso)
